Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
Aeglea BioTherapeutics (Nasdaq:AGLE) reported its Q2 2021 financial results, showcasing significant progress in its clinical programs and corporate structure. The company initiated dosing in its Phase 1/2 trial of AGLE-177 for Homocystinuria and published data on pegzilarginase for Arginase 1 Deficiency, with results expected in Q4 2021.
Financially, Aeglea recorded $13.7 million in license and development revenues, with a net loss of $6.8 million. Cash reserves stood at $130.4 million, enabling operations through 2023.
- Initiated Phase 1/2 clinical trial for AGLE-177 in Homocystinuria.
- Achieved $13.7 million in license and development revenues for Q2 2021.
- Reduced research and development expenses to $13.6 million from $16.9 million year-over-year.
- Net loss of $6.8 million for Q2 2021, though improved from $21.4 million in Q2 2020.
- General and administrative expenses increased to $6.8 million, up from $4.7 million year-over-year.
AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights.
"2021 is proving to be a pivotal year for Aeglea. In the second quarter, we achieved a significant milestone in our second clinical development program. With the initiation of dosing in our Phase 1/2 clinical trial of AGLE-177, Aeglea is making progress for patients who suffer from Homocystinuria, a rare and progressive disease which currently has limited treatment options," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Additionally, with the strengthening of our leadership team, deepening relationship with the rare disease community and advancing our scientific communications platform, we continue to prepare for the data readout for our Phase 3 clinical trial of pegzilarginase in Arginase 1 Deficiency in the fourth quarter as well as lay the groundwork for potential approval and commercialization."
Second Quarter and Recent Highlights and Updates
AGLE-177 in Homocystinuria
- Initiated dosing with AGLE-177 in a Phase 1/2 clinical trial in people with Homocystinuria. The trial is anticipated to enroll 16–20 patients at sites located in the United Kingdom and Australia. Aeglea expects to provide a clinical update prior to the end of 2021.
Pegzilarginase in Arginase 1 Deficiency
- Published 20-week data from a Phase 1/2 and open-label extension studies of pegzilarginase in the Journal of Inherited Metabolic Disease. The article, titled "Clinical Effect and Safety Profile of Pegzilarginase In Patients with Arginase 1 Deficiency," is available in the July issue.
Corporate
- Strengthened the leadership team with appointment of Jonathan Alspaugh as chief financial officer and Jim Kastenmayer as general counsel.
- Mr. Alspaugh joined Aeglea from Evercore, where he most recently served as a managing director in the firm's corporate advisory business.
- Mr. Kastenmayer joined Aeglea from Viela Bio, where he provided strategic guidance and legal advice, including advising Viela in connection with the FDA approval and launch of its first commercial product.
- Expanded the board of directors with the appointment of Marcio Souza. Mr. Souza serves as the president & chief executive officer of Praxis Precision Medicines.
- Participated in Rare Disease Awareness Week on Capitol Hill 2021, meeting with patient advocates and law makers to raise awareness and discuss the specific needs facing the rare disease community.
- Supported the launch of the Rare Disease Company Coalition, a unified voice of life science companies committed to discovering, developing and delivering rare disease treatments, of which Aeglea is a founding member.
Upcoming Investor Events
- Wells Fargo 2021 Virtual Healthcare Conference, September 9–10
- HC Wainwright 23rd Annual Global Investment Conference, September 13–15
- 2021 Cantor Virtual Healthcare Conference, September 27–30
Second Quarter 2021 Financial Results
As of June 30, 2021, Aeglea had available cash, cash equivalents, marketable securities and restricted cash of
Aeglea recognized license and development revenues of
Research and development expenses totaled
General and administrative expenses totaled
Net loss totaled
About Pegzilarginase in Arginase 1 Deficiency
Pegzilarginase is a novel recombinant human enzyme, which has been shown to rapidly and sustainably lower levels of the amino acid arginine in plasma. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D), a rare debilitating and progressive disease characterized by the accumulation of arginine. ARG1-D presents in early childhood and patients experience spasticity, seizures, developmental delay, intellectual disability and early mortality. Aeglea's Phase 1/2 and Phase 2 open-label extension data for pegzilarginase in patients with ARG1-D demonstrated clinical improvements and sustained lowering of plasma arginine. The Company's ongoing single, global pivotal Phase 3 PEACE trial is designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction. Pegzilarginase has received multiple regulatory designations, including Rare Pediatric Disease, Breakthrough, Fast Track and Orphan Drug Designations from the FDA as well as Orphan Drug Designation from the European Medicines Agency.
About AGLE-177 in Homocystinuria
AGLE-177 is a novel recombinant human enzyme, which degrades the amino acid homocysteine and its related homocystine dimer. AGLE-177 is currently being studied in a Phase 1/2 clinical trial for the treatment of patients with Classical Homocystinuria, a rare inherited disorder of methionine metabolism that results in elevated levels of homocysteine and homocystine. Homocysteine accumulation plays a key role in multiple progressive and serious disease-related complications, including thromboembolic vascular events, skeletal abnormalities (including severe osteoporosis), developmental delay, intellectual disability, lens dislocation and severe near sightedness. Preclinical data demonstrated that AGLE-177, which is designed to lower abnormally high blood levels of homocysteine, improved important disease-related abnormalities and survival in a mouse model of Homocystinuria. AGLE-177 has received both U.S. and EU Orphan Drug Designation as well as U.S. Rare Pediatric Disease Designation.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company began dosing patients in a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in June 2021. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.
Safe Harbor / Forward Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our ability to obtain regulatory approval for, and commercialize, pegzilarginase, recognize milestone and royalty payments from our agreement with Immedica, cash forecasts, the timing and success of our clinical trials and related data, the timing and expectations for regulatory submissions and approvals, timing and results of meetings with regulators, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, the expected impact of the COVID-19 pandemic on our operations and clinical trials, success in our collaborations, the potential addressable markets of our product candidates and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Annual Report on Form 10-Q for the quarter ended June 30, 2021 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Financials
Aeglea BioTherapeutics, Inc. | ||||||||
June 30, | December 31, | |||||||
2021 | 2020 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 34,765 | $ | 90,095 | ||||
Marketable securities | 93,813 | 56,178 | ||||||
Prepaid expenses and other current assets | 5,790 | 3,516 | ||||||
Total current assets | 134,368 | 149,789 | ||||||
Restricted cash | 1,846 | 1,842 | ||||||
Property and equipment, net | 5,208 | 5,642 | ||||||
Operating lease right-of-use assets | 4,012 | 4,230 | ||||||
Other non-current assets | 1,548 | 115 | ||||||
TOTAL ASSETS | $ | 146,982 | $ | 161,618 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
CURRENT LIABILITIES | ||||||||
Accounts payable | $ | 2,221 | $ | 2,254 | ||||
Operating lease liabilities | 412 | 319 | ||||||
Deferred revenue | 5,530 | — | ||||||
Accrued and other current liabilities | 12,441 | 13,870 | ||||||
Total current liabilities | 20,604 | 16,443 | ||||||
Non-current operating lease liabilities | 4,880 | 5,129 | ||||||
Deferred revenue, net of current portion | 2,274 | — | ||||||
Other non-current liabilities | 200 | 214 | ||||||
TOTAL LIABILITIES | 27,958 | 21,786 | ||||||
STOCKHOLDERS' EQUITY | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 5 | 5 | ||||||
Additional paid-in capital | 420,064 | 415,824 | ||||||
Accumulated other comprehensive income | 11 | 11 | ||||||
Accumulated deficit | (301,056) | (276,008) | ||||||
TOTAL STOCKHOLDERS' EQUITY | 119,024 | 139,832 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 146,982 | $ | 161,618 | ||||
Aeglea BioTherapeutics, Inc. | |||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||
Revenue: | |||||||||||||||||
License | $ | 12,000 | $ | — | $ | 12,000 | $ | — | |||||||||
Development fee | 1,696 | — | 1,696 | — | |||||||||||||
Total revenue | 13,696 | — | 13,696 | — | |||||||||||||
Operating expenses: | |||||||||||||||||
Research and development | 13,579 | 16,869 | 25,434 | 31,431 | |||||||||||||
General and administrative | 6,822 | 4,691 | 13,176 | 9,151 | |||||||||||||
Total operating expenses | 20,401 | 21,560 | 38,610 | 40,582 | |||||||||||||
Loss from operations | (6,705) | (21,560) | (24,914) | (40,582) | |||||||||||||
Other income (expense): | |||||||||||||||||
Interest income | 19 | 161 | 41 | 461 | |||||||||||||
Other expense, net | (52) | (19) | (83) | (25) | |||||||||||||
Total other income (expense) | (33) | 142 | (42) | 436 | |||||||||||||
Loss before income tax expense | (6,738) | (21,418) | (24,956) | (40,146) | |||||||||||||
Income tax expense | (92) | — | (92) | — | |||||||||||||
Net loss | $ | (6,830) | $ | (21,418) | $ | (25,048) | $ | (40,146) | |||||||||
Net loss per share, basic and diluted | $ | (0.10) | $ | (0.40) | $ | (0.38) | $ | (0.93) | |||||||||
Weighted-average common shares outstanding, basic and diluted | 65,631,906 | 52,941,603 | 65,618,207 | 43,019,670 | |||||||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-reports-second-quarter-2021-financial-results-and-corporate-highlights-301348486.html
SOURCE Aeglea BioTherapeutics, Inc.
FAQ
What were Aeglea's Q2 2021 financial results?
What is AGLE-177 and its significance?
When can we expect results from the pegzilarginase trial?
What is Aeglea's cash position as of June 30, 2021?
How have Aeglea's expenses changed in Q2 2021?
